Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenhydramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.89 |
| ▸ | DRD3 | P35462 | 3/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.89 |
| ▸ | SCN1A | P35498 | 3/20 | 0.89 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.89 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.89 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.89 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.89 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.89 |
| ▸ | HRH2 | P25021 | 2/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenhydramine SCHEMBL4064 | 0.94 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL12543374 | 0.94 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL2503935 | 0.94 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL29205078 | 0.93 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL9565209 | 0.93 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL25219551 | 0.93 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL17071 | 0.93 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL28210970 | 0.93 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL10487818 | 0.93 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL11795332 | 0.93 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530582-A4 | DIAGNOSIS OF KIDNEY DAMAGE AND PROTECTION AGAINST SAME | UNIV OHIO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1530582-A2 | DIAGNOSIS OF KIDNEY DAMAGE AND PROTECTION AGAINST SAME | Ohio University (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004013289-A9 | DIAGNOSIS OF KIDNEY DAMAGE AND PROTECTION AGAINST SAME | UNIV OHIO (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004013289-A2 | DIAGNOSIS OF KIDNEY DAMAGE AND PROTECTION AGAINST SAME | OHIO UNIVERSITY (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1360501-A2 | METHOD OF IDENTIFYING CONFORMATION-SENSITIVE BINDING PEPTIDES AND USES THEREOF | Karo Bio USA, Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002004956-A2 | METHOD OF IDENTIFYING CONFORMATION-SENSITIVE BINDING PEPTIDES AND USES THEREOF | KARO BIO USA, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1073891-A2 | METHOD OF PREDICITING RECEPTOR MODULATING ACTIVITY | Karo Bio USA, Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1002235-A1 | METHOD OF IDENTIFYING AND DEVELOPING DRUG LEADS | Novalon Pharmaceutical Corporation (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999054728-A2 | METHOD OF PREDICTING RECEPTOR MODULATING ACTIVITY | KARO BIO USA, INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0937253-A1 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | Novalon Pharmaceutical Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999006839-A1 | METHOD OF IDENTIFYING AND DEVELOPING DRUG LEADS | NOVALON PHARMACEUTICAL CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998019162-A9 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | — | 1998-07-09 | — | — | WO | disclosed |
| WO-1998019162-A1 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | NOVALON PHARMACEUTICAL CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |